News – Page 1170 – Endpoints News

Protocols: Editas recruits a Bristol-Myers vet as CSO; Eli Lilly gets a dubious honor for Alzheimer's drug; Voyager ...

9 years ago

Sanofi can’t even buy a break now, as rival Novo speeds ahead on diabetes showdown

9 years ago

BioRegnum snapshot: Who are the real insiders when it comes to healthcare policy?

9 years ago

Low-profile Thar Pharma takes a $50M flier on a weak IPO market

9 years ago

Axel Bouchon starts signing players for a new league of game-changing biotechs

9 years ago

Pfizer bags Medivation buyout with blowout $14B cash offer

9 years ago

Protocols: Calico recruits a machine learning star for computational biology; OncoMed raises $55M

9 years ago

Golden Triangle gets £75M in fresh venture funds for Cambridge U spinouts

9 years ago

Chinese development group blueprints $1B-plus biotech campus in South San Francisco

9 years ago

Thumbs Up. Thumbs Down: On rookie mistakes, a class action suit and getting past failure

9 years ago

Welcome Casebia, the $335M gene editing JV hatched by Bayer and CRISPR Therapeutics

9 years ago

Following another PhII failure, cash-strapped Cerulean chops half its staff

9 years ago

Protocols: Mallinckrodt lands a new corporate campus in NJ; Nutrinia bags a $30M round for oral insulin

9 years ago

BioRegnum: The fog of M&A. What constitutes a legit buyout ‘scoop’ these days?

9 years ago

Auris shares are crushed as tinnitus drug fails PhIII test

9 years ago

Expanded syndicate puts Avelas onto the PoC track with $20M cancer tech round

9 years ago

Portola slammed by a surprising FDA rejection for its anti-anticoagulant

9 years ago

Cerulean crashes after lead nano drug flubs its second PhII cancer study

9 years ago

Protocols: Indivior claims PhIII success, points to 2017 FDA OK; InVivo touts another patient response in spinal ...

9 years ago

Controversial patient deaths in CAR-T study spur a class action suit against Juno

9 years ago

RIP: After burning through $463M, StemCells’ corpse is bought out for the public shell

9 years ago

The $140,672,343 man: Why does Brent Saunders have the richest golden parachute in biopharma?

9 years ago

Split the pot? Radius shows its osteoporosis cards in final blockbuster match with Amgen

9 years ago

Protocols: Snubbed at the FDA, again, Chiasma chops staff, again; J&J lands second BTD for depression drug esketamine

9 years ago

First page Previous page 1167 1168 116911701171 1172 1173 Next page Last page